Pyrotinib is considered to have potential therapeutic benefits in patients with HER2 mutations.35 A single-arm, prospective, phase-II study on the therapeutic efficacy of pyrotinib in metastatic BC with HER2 mutations in 10 patients13 reported that 1 patient experienced complete response and 3 patients experienced partial response. This evidence concerns the gene ERBB2 and breast cancer.